Hainan Poly Pharm. Co., Ltd

Equities

300630

CNE100002N10

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
14.67 CNY +0.96% Intraday chart for Hainan Poly Pharm. Co., Ltd +1.10% -35.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hainan Poly Pharm Gets Nod to Market Voriconazole Injection in Sweden MT
Hainan Poly Pharm Gets Nod to Market Skin Infection Drug in Germany MT
Hainan Poly Pharm's Brivaracetam Injection Gets FDA's Nod to Enter US Market; Shares Up 3% MT
Hainan Poly Pharm's Epilepsy Drug Gets FDA's Greenlight to Enter US Market MT
Hainan Poly Pharm to Apply For Up to 3.8 Billion Yuan Credit Line MT
Hainan Poly Pharm Gets Nod to Market Pantoprazole Sodium for Injection in Singapore MT
Hainan Poly Pharm. Co., Ltd(SZSE:300630) dropped from Shenzhen Stock Exchange Component A Share Index CI
Hainan Poly Pharm. Co., Ltd(SZSE:300630) dropped from Shenzhen Stock Exchange Component Index CI
Hainan Poly Pharm. Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hainan Poly Pharm's Gets US FDA Nod to Market Iopamidol Injection MT
Hainan Poly Pharm Gets Approval to Market Fluconazole Dry Suspension in US MT
Tranche Update on Hainan Poly Pharm. Co., Ltd's Equity Buyback Plan announced on April 25, 2023. CI
Hainan Poly Pharm. Co., Ltd's Equity Buyback announced on April 25, 2023 has closed with 1,426,700 shares, representing 0.33% for CNY 30.03 million. CI
Hainan Poly Pharm's Unit Passes US FDA's On-Site Inspection MT
Hainan Poly Pharm. Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hainan Poly Pharm's Unit Passes Regulator's GMP Inspection MT
Hainan Poly Pharm Wins FDA Nod to Market Azithromycin Variant in US MT
Hainan Poly Pharm. Co., Ltd Announces Dividend Implementation of Cash Dividend for 2022, Payable on 18 July 2023 CI
Tranche Update on Hainan Poly Pharm. Co., Ltd's Equity Buyback Plan announced on April 25, 2023. CI
Hainan Poly Pharm. Co.,Ltd Approves Cash Dividend for 2022 CI
Hainan Poly Pharm Gets Regulatory OK to Convert Desloratadine Dispersible Tablets into Over-The-Counter Drugs MT
Hainan Poly Pharm. Co.,Ltd Proposes Final Profit Distribution for 2022 CI
Hainan Poly Pharm. Co., Ltd announces an Equity Buyback for CNY 60 million worth of its shares. CI
Hainan Poly Pharm. Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hainan Poly Pharm. Co., Ltd authorizes a Buyback Plan. CI
Chart Hainan Poly Pharm. Co., Ltd
More charts
Hainan Poly Pharm Co Ltd is a company engaged in research and development, production and sales of drugs. The Company operates five segments. The Anti-Allergic segment is engaged in the production of desloratadine dispersible tablets, desloratadine dry suspension and desloratadine tablets. The Antibiotic segment provides levofloxacin hydrochloride capsules and azithromycin dry suspension for the treatment of bacterial infections. The Nonsteroidal Anti-inflammatory Drugs segment provides diclofenac sodium enteric-coated sustained-release capsule products for the treatment of arthritis and dysmenorrhea. The Digestive segment is involved in providing trimebutine maleate tablets to treat abdominal pain, diarrhea, and irritable bowel syndrome. The Company also operates Other segment.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
14.67
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300630 Stock
  4. News Hainan Poly Pharm. Co., Ltd
  5. Hainan Poly Pharm's Brivaracetam Injection Gets FDA's Nod to Enter US Market; Shares Up 3%